Kalaris Therapeutics (KLRS) Competitors $2.76 -0.08 (-2.82%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsTrendsBuy This Stock KLRS vs. BDTX, GALT, IPHA, SLS, ACRS, IMAB, TIL, PBYI, KYTX, and DERMShould you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Innate Pharma (IPHA), SELLAS Life Sciences Group (SLS), Aclaris Therapeutics (ACRS), I-Mab (IMAB), Instil Bio (TIL), Puma Biotechnology (PBYI), Kyverna Therapeutics (KYTX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Kalaris Therapeutics vs. Its Competitors Black Diamond Therapeutics Galectin Therapeutics Innate Pharma SELLAS Life Sciences Group Aclaris Therapeutics I-Mab Instil Bio Puma Biotechnology Kyverna Therapeutics Journey Medical Black Diamond Therapeutics (NASDAQ:BDTX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Do analysts prefer BDTX or KLRS? Black Diamond Therapeutics presently has a consensus target price of $12.80, suggesting a potential upside of 330.98%. Kalaris Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 8.70%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is BDTX or KLRS more profitable? Black Diamond Therapeutics' return on equity of 4.70% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A 4.70% 3.47% Kalaris Therapeutics N/A -62.08%-54.69% Do institutionals & insiders have more ownership in BDTX or KLRS? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 6.0% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, BDTX or KLRS? Black Diamond Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Which has preferable valuation & earnings, BDTX or KLRS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$69.68M$0.0649.50Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A Does the media prefer BDTX or KLRS? In the previous week, Kalaris Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 2 mentions for Kalaris Therapeutics and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.91 beat Kalaris Therapeutics' score of 1.44 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Black Diamond Therapeutics Very Positive Kalaris Therapeutics Positive SummaryBlack Diamond Therapeutics beats Kalaris Therapeutics on 8 of the 11 factors compared between the two stocks. Get Kalaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.61M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A21.1828.1120.03Price / SalesN/A339.43461.37103.88Price / CashN/A43.2336.5559.01Price / Book0.128.368.655.90Net Income-$58.77M-$55.19M$3.25B$258.66M7 Day Performance15.48%5.89%4.21%2.22%1 Month Performance6.15%17.63%10.82%12.76%1 Year PerformanceN/A5.09%34.70%19.36% Kalaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSKalaris Therapeutics0.8869 of 5 stars$2.76-2.8%$3.00+8.7%N/A$51.61MN/A0.00110Analyst ForecastBDTXBlack Diamond Therapeutics2.9635 of 5 stars$3.13-2.5%$12.80+308.9%-48.7%$177.98MN/A52.1790Positive NewsGALTGalectin Therapeutics2.4432 of 5 stars$2.80-3.1%$6.00+114.3%+14.0%$177.22MN/A-3.899IPHAInnate Pharma2.6261 of 5 stars$1.92+8.5%$11.00+472.9%-10.0%$176.98M$12.62M0.00220Gap UpSLSSELLAS Life Sciences Group2.3325 of 5 stars$1.77-6.8%$7.00+295.5%+53.8%$176.61MN/A-4.6610Positive NewsACRSAclaris Therapeutics2.3799 of 5 stars$1.61+1.3%$8.71+441.3%+21.7%$174.33M$18.72M-1.16100Positive NewsGap UpIMABI-Mab2.869 of 5 stars$2.10-2.8%$6.00+185.7%+50.4%$171.49M$3.89M0.00380TILInstil Bio3.1676 of 5 stars$26.10-5.8%$119.00+355.9%+151.7%$171.19MN/A-2.18410Positive NewsPBYIPuma Biotechnology4.233 of 5 stars$3.40+1.2%$7.00+105.9%-8.8%$168.75M$230.50M4.42200Upcoming EarningsKYTXKyverna Therapeutics2.7116 of 5 stars$3.90-4.2%$18.50+374.4%-52.5%$168.55MN/A-1.1596DERMJourney Medical2.331 of 5 stars$7.19-1.5%$9.50+32.1%+42.0%$167.50M$56.13M-18.4490 Related Companies and Tools Related Companies BDTX Competitors GALT Competitors IPHA Competitors SLS Competitors ACRS Competitors IMAB Competitors TIL Competitors PBYI Competitors KYTX Competitors DERM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.